Artivion (NYSE:AORT) Raised to “Buy” at Wall Street Zen

Artivion (NYSE:AORT) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Monday.

A number of other research analysts have also recently issued reports on the stock. Needham & Company LLC boosted their price objective on shares of Artivion from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday. Stifel Nicolaus boosted their price objective on shares of Artivion from $36.00 to $40.00 and gave the company a “buy” rating in a report on Friday, August 8th. JMP Securities boosted their price objective on shares of Artivion from $33.00 to $42.00 and gave the company a “market outperform” rating in a report on Friday, August 8th. LADENBURG THALM/SH SH cut shares of Artivion from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $32.00 to $38.80 in a report on Wednesday, August 13th. Finally, Canaccord Genuity Group boosted their price objective on shares of Artivion from $35.00 to $41.00 and gave the company a “buy” rating in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Artivion has an average rating of “Buy” and a consensus price target of $40.63.

Artivion Stock Up 3.9%

Shares of NYSE:AORT opened at $44.8140 on Monday. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -106.70 and a beta of 1.64. The company has a 50 day moving average of $33.65 and a 200-day moving average of $28.83. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. Artivion has a one year low of $21.97 and a one year high of $45.07.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.13. The firm had revenue of $112.97 million during the quarter, compared to analysts’ expectations of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Artivion will post 0.37 earnings per share for the current year.

Insider Activity at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 26,132 shares of Artivion stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $28.44, for a total value of $743,194.08. Following the transaction, the senior vice president owned 79,200 shares of the company’s stock, valued at approximately $2,252,448. The trade was a 24.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Jean F. Holloway sold 23,356 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $43.01, for a total transaction of $1,004,541.56. Following the completion of the sale, the senior vice president directly owned 172,129 shares in the company, valued at approximately $7,403,268.29. This represents a 11.95% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 96,538 shares of company stock worth $3,444,651. Corporate insiders own 8.10% of the company’s stock.

Institutional Trading of Artivion

Institutional investors have recently made changes to their positions in the business. Legacy Advisors LLC bought a new stake in shares of Artivion in the first quarter worth $28,000. MCF Advisors LLC lifted its position in shares of Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after purchasing an additional 614 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Artivion in the fourth quarter worth $64,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Artivion by 447.6% in the second quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company’s stock worth $168,000 after purchasing an additional 4,422 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.